CIM22LAPP1C-10 is an intermediate-maturing, high-yielding, yellow maize hybrid with TSC, MLB and Ear rots resistance. The product is notable for its high optimum yield, excellent synchrony, low ear position, semi-flint grain and resistance to root lodging and is suitable for feed use in tropical rainfed low-altitude areas in Latin America. |
|
General Information |
|
Target Region |
Latin America |
|
Adaptation/Agroecological zone |
0 - 1200m above sea level |
|
Type of product |
Three-way hybrid |
|
Year first announced |
2024 |
|
|
|
|
Grain Characteristics |
|
|
|
Grain color |
Yellow |
Abiotic Stress Performance |
|
Grain texture |
Semi-flint |
Grain yield under optimum conditions |
8.47 t/ha |
|
|
|
Grain yield under rainfed conditions |
4.59 t/ha |
|
Biotic Stress Performance |
Grain yield on-farm (avg) |
6.49 t/ha |
|
Maydis leaf blight (MLB) (1-9)* |
2.9 |
Grain yield on-farm (opt.) |
8.35 t/ha |
|
Tar Spot Complex (TSC) (1-9)* |
4.1 |
Grain yield on-farm (rainfed) |
4.87 t/ha |
|
Ear Rots (%) |
6.4% |
|
|
|
*Scored on 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible |
Agronomic Characteristics |
|
Maturity group |
Intermediate |
|
|
|
50% anthesis |
58 DAP |
|
Seed Production Characteristics |
Plant height |
241 cm |
|
SC female parent seed yield |
9.8 t/ha |
Ear height |
118 cm |
|
Male seed yield |
4.2 t/ha |
Ear position (ratio) |
0.49 |
|
Nicking |
0 days |
Ears per plant |
0.99 |
|
|
|
Ear aspect (1-9)* |
4.5 |
|
Comments |
Plant aspect (1-9)* |
4.7 |
|
Product information is based on data from the 2022 CIMMYT LatAm Stage 4 Regional Trials and 2023 Stage 5 Trials. Actual performance will vary depending on a number of agronomic and environmental factors.
Abbreviations:
DAP = days after planting
SC = Single-cross
MLB = Maydis leaf blight
TSC = Tar spot complex |
Bad husk cover |
2.7% |
|
Root lodging |
2.9% |
|
Stalk lodging |
9.1% |
|
Anther-silking interval |
1 day |
|
*Plant and ear aspects are scored on 1-9 scale, where 1 = desirable and 9 = undesirable characteristics |
|
|
|
|
|
Further Links |
|
Full Announcement & trial data |
|
|